广东省重组人凝血因子Ⅷ药物评价与遴选专家共识
Expert Consensus on Evaluation and Selection of Recombinant Human Coagulation Factor Ⅷ in Guangdong
广东省药学会药物警戒专业委员会 陈娟 1郑萍1
作者信息
- 1. 南方医科大学南方医院药学部;南方医科大学南方医院临床药学中心
- 折叠
摘要
重组人凝血因子Ⅷ为众多权威指南推荐的血友病A首选替代治疗药物.重组人凝血因子Ⅷ各品种能够暂时替代患者体内缺失的凝血因子Ⅷ,具有相同的药物作用机制,但在经济性、药学特性及其他属性等方面存在差异.为此,广东省药学会药物警戒专业委员会组织药学与临床专家共同制定了《广东省重组人凝血因子Ⅷ药物评价与遴选专家共识》,对我国已上市的 6 种重组人凝血因子Ⅷ从药学特性、有效性、安全性、经济性及其他属性等五大方面进行多维度评价,为医疗机构药品遴选及临床合理用药提供参考依据.
Abstract
Recombinant human coagulation factor Ⅷ is the first-line treatment for hemophilia A recommended by authoritative guidelines.Various recombinant human coagulation factor Ⅷ have the same mechanism of action,which can temporarily replace the missing clotting factor Ⅷ that is needed for effective hemostasis in patients.There are differences in economy,pharmaceutical characteristics and other attributes.Therefore,pharmaceutical and clinical experts are organized by the Pharmacovigilance Professional Committee of Guangdong Pharmaceutical Association to formulate the Expert Consensus on Evaluation and Selection of Recombinant Human Coagulation Factor Ⅷ in Guangdong.Multi-dimensional evaluation on 6 kinds of recombinant human coagulation factor Ⅷ marketed in China are carried out from five aspects:pharmaceutical characteristics,efficacy,safety,economy and other attributes,so as to provide scientific basis for drug selection in medical institutions and promotes rational drug use in clinic.
关键词
血友病A/重组人凝血因子Ⅷ/药物评价/遴选/专家共识Key words
Hemophilia A/Recombinant human coagulation factor Ⅷ/Drug evaluation/Selection/Expert consensus引用本文复制引用
基金项目
国家重点研发计划项目(2020YFC2005501)
出版年
2024
国家科技期刊平台
NSTL
万方数据